Generation of IPS Cells from Normal and Malignant Hematopoietic Cells

Overview

Journal Int J Hematol

Specialty Hematology

Date 2013 Jun 29

PMID 23807288

Citations 6

Authors

Keiki Kumano

Shunya Arai

Mineo Kurokawa

Affiliations

Soon will be listed here.

Abstract

Induced pluripotent stem cells (iPSCs) can be generated from various types of cells with transduction of defined transcription factors. In addition to regenerative medicine, iPSCs have been used for the study of pathogenesis of inherited genetic diseases. Here, we presented the examples of the establishment of iPSCs from hematopoietic cells or fibroblasts from hematological disease patients. Hematopoietic cells would be a good donor source for establishing iPSCs owing to the high reprogramming efficiency. iPSCs can be generated not only from normal cells, but also from several types of tumor cells. However it is not so easy, because iPSCs from hematological malignancies have been established only from myeloproliferative neoplasms including chronic myelogenous leukemia (CML) and JAK2-V617F mutation-positive polycythemia vera (PV). iPSC technology has great potential to promote oncology research based on patient samples.

Citing Articles

The Stem Cell Revolution Revealing Protozoan Parasites' Secrets and Paving the Way towards Vaccine Development.

Pance A Vaccines (Basel). 2021; 9(2).

PMID: 33572549 PMC: 7911700. DOI: 10.3390/vaccines9020105.

Immortalized murine fibroblast cell lines are refractory to reprogramming to pluripotent state.

Skvortsova E, Sinenko S, Tomilin A Oncotarget. 2018; 9(81):35241-35250.

PMID: 30443291 PMC: 6219659. DOI: 10.18632/oncotarget.26235.

Reprogramming bladder cancer cells for studying cancer initiation and progression.

Iskender B, Izgi K, Canatan H Tumour Biol. 2016; 37(10):13237-13245.

PMID: 27456363 DOI: 10.1007/s13277-016-5226-4.

Genomic editing tools to model human diseases with isogenic pluripotent stem cells.

Kim H, Bernitz J, Lee D, Lemischka I Stem Cells Dev. 2014; 23(22):2673-86.

PMID: 25075441 PMC: 4216528. DOI: 10.1089/scd.2014.0167.

Reprogramming cancer cells to pluripotency: an experimental tool for exploring cancer epigenetics.

Stricker S, Pollard S Epigenetics. 2014; 9(6):798-802.

PMID: 24686321 PMC: 4065176. DOI: 10.4161/epi.28600.

References

Zou J, Mali P, Huang X, Dowey S, Cheng L . Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood. 2011; 118(17):4599-608. PMC: 3208277. DOI: 10.1182/blood-2011-02-335554. View

Staerk J, Dawlaty M, Gao Q, Maetzel D, Hanna J, Sommer C . Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell. 2010; 7(1):20-4. PMC: 2917234. DOI: 10.1016/j.stem.2010.06.002. View

Raya A, Rodriguez-Piza I, Guenechea G, Vassena R, Navarro S, Barrero M . Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature. 2009; 460(7251):53-9. PMC: 2720823. DOI: 10.1038/nature08129. View

Eminli S, Foudi A, Stadtfeld M, Maherali N, Ahfeldt T, Mostoslavsky G . Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet. 2009; 41(9):968-76. PMC: 3987895. DOI: 10.1038/ng.428. View

Giorgetti A, Montserrat N, Aasen T, Gonzalez F, Rodriguez-Piza I, Vassena R . Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell. 2009; 5(4):353-7. PMC: 2779776. DOI: 10.1016/j.stem.2009.09.008. View

Ye Z, Zhan H, Mali P, Dowey S, Williams D, Jang Y . Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood. 2009; 114(27):5473-80. PMC: 2798863. DOI: 10.1182/blood-2009-04-217406. View

Hu K, Yu J, Suknuntha K, Tian S, Montgomery K, Choi K . Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood. 2011; 117(14):e109-19. PMC: 3083304. DOI: 10.1182/blood-2010-07-298331. View

Carette J, Pruszak J, Varadarajan M, Blomen V, Gokhale S, Camargo F . Generation of iPSCs from cultured human malignant cells. Blood. 2010; 115(20):4039-42. PMC: 2875096. DOI: 10.1182/blood-2009-07-231845. View

Ye L, Chang J, Lin C, Sun X, Yu J, Kan Y . Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases. Proc Natl Acad Sci U S A. 2009; 106(24):9826-30. PMC: 2701047. DOI: 10.1073/pnas.0904689106. View

10.

Zou J, Sweeney C, Chou B, Choi U, Pan J, Wang H . Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood. 2011; 117(21):5561-72. PMC: 3110021. DOI: 10.1182/blood-2010-12-328161. View

11.

Han J, Sachdev P, Sidhu K . A combined epigenetic and non-genetic approach for reprogramming human somatic cells. PLoS One. 2010; 5(8):e12297. PMC: 2924394. DOI: 10.1371/journal.pone.0012297. View

12.

Park I, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A . Disease-specific induced pluripotent stem cells. Cell. 2008; 134(5):877-86. PMC: 2633781. DOI: 10.1016/j.cell.2008.07.041. View

13.

Chou S, Byrska-Bishop M, Tober J, Yao Y, VanDorn D, Opalinska J . Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells. Proc Natl Acad Sci U S A. 2012; 109(43):17573-8. PMC: 3491490. DOI: 10.1073/pnas.1211175109. View

14.

Muller L, Milsom M, Harris C, Vyas R, Brumme K, Parmar K . Overcoming reprogramming resistance of Fanconi anemia cells. Blood. 2012; 119(23):5449-57. PMC: 3369681. DOI: 10.1182/blood-2012-02-408674. View

15.

Park I, Zhao R, West J, Yabuuchi A, Huo H, Ince T . Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2007; 451(7175):141-6. DOI: 10.1038/nature06534. View

16.

Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663-76. DOI: 10.1016/j.cell.2006.07.024. View

17.

Li M, Suzuki K, Qu J, Saini P, Dubova I, Yi F . Efficient correction of hemoglobinopathy-causing mutations by homologous recombination in integration-free patient iPSCs. Cell Res. 2011; 21(12):1740-4. PMC: 3357996. DOI: 10.1038/cr.2011.186. View

18.

Hanna J, Wernig M, Markoulaki S, Sun C, Meissner A, Cassady J . Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 2007; 318(5858):1920-3. DOI: 10.1126/science.1152092. View

19.

Izpisua Belmonte J, Ellis J, Hochedlinger K, Yamanaka S . Induced pluripotent stem cells and reprogramming: seeing the science through the hype. Nat Rev Genet. 2009; 10(12):878-83. DOI: 10.1038/nrg2700. View

20.

Nakatsuji N, Nakajima F, Tokunaga K . HLA-haplotype banking and iPS cells. Nat Biotechnol. 2008; 26(7):739-40. DOI: 10.1038/nbt0708-739. View